Genprex shares surge 27.53% intraday after securing Japanese and EU patents for Reqorsa® gene therapy in cancer treatment combinations.

Genprex (NASDAQ: GNPX) surged 27.53% intraday following announcements that the Japanese Patent Office and European Patent Office granted patents for its Reqorsa® gene therapy in combination with PD-1/PD-L1 antibodies to treat cancer. These approvals strengthen Genprex’s intellectual property portfolio, particularly for its Acclaim-3 clinical trial targeting small cell lung cancer. The patents, covering key markets, provide global protection for therapeutic combinations and validate the company’s strategy of leveraging gene therapy alongside immunotherapies. The news reinforced investor confidence in Genprex’s ability to secure IP in critical jurisdictions, reduce competitive risks, and advance its oncology pipeline, directly driving the intraday price spike.